Cutia Therapeutics
科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2487)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025

The Board is pleased to announce the unaudited consolidated interim results of the Group for the six months ended 30 June 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

Founded in 2019, we are a R&D-driven, dermatology innovative products-focused biopharmaceutical company committed to developing comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. We have built a broad portfolio of products, targeting the four main sectors of the broader dermatology treatment and care market, namely scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management. We currently have two main products with marketing approval and one drug marketing authorization application that has been accepted by the NMPA. We have also distributed several commercialized products developed by overseas collaboration partners and marketed several products in China.

We are one of the few players in the broader dermatology treatment and care market in China equipped with fully integrated capabilities. We have applied a customer-centric approach to bolster our product candidates and expand our integrated capabilities to the entire broader dermatology treatment and care industry value chain. Our platform spans from the early phase of identifying demands, developing core technologies, managing clinical trials and product registrations, to the manufacturing and marketing of products.

Our proprietary CATAME® technology platform improves drugs to achieve topical or transdermal delivery by developing micron and nano-sized particulates, as well as evaluating formulation quality and stability, and performing cutaneous pharmacokinetic analysis. Our platform also helps design the most suitable product formats that are keys to specific and successful drug delivery. Through this platform, we have built a competitive product pipeline of creams, sprays, ointments, aerosol foams and other dosage forms.

BUSINESS REVIEW

As at the date of this announcement, the Group had a number of scalp diseases and care products and skin care products on sale. The Group's CU-10201 (topical 4% minocycline foam) and CU-40102 (topical finasteride spray) have obtained marketing approval from the NMPA, CU-40102 has also obtained marketing approval from the Hong Kong Department of Health. Meanwhile, drug marketing authorization application for the Group's CU-30101 (localized topical lidocaine and tetracaine cream) has been accepted by the NMPA. We have achieved the following significant advancements in both pipeline products and business operations.

Scalp Diseases and Care

Key Product CU-40102 (topical finasteride spray)

– CU-40102 is the first and only topical finasteride product approved for androgenetic alopecia treatment globally and the first topical finasteride to obtain marketing approval from the NMPA. Finasteride can treat androgenetic alopecia in male patients by acting as a competitive and specific inhibitor of Type II 5-alpha reductase to inhibit the conversion of testosterone to DHT in the scalp.

– Unlike oral finasteride, CU-40102's topical formulation allows patients to apply the drug directly to the surface of the scalp, thereby maintaining a high concentration at the affected site and reducing the systemic exposure of the drug compared with oral formulations.

– CU-40102 obtained marketing approval from the NMPA in June 2025 and from the Hong Kong Department of Health in August 2025, with an approved indication for the treatment of androgenetic alopecia. We are currently actively preparing for its commercialization activities.

– The marketing approval for CU-40102 was primarily based on the results of its Phase I and Phase III pivotal clinical trials completed in China. The clinical trials demonstrated that CU-40102 was effective in treating androgenetic alopecia and also showed a favorable local tolerance to the administration area.

Skin Diseases and Care

Key Product CU-10201 (topical 4% minocycline foam)

– CU-10201 is the first and only topical minocycline approved for acne vulgaris treatment globally and the first topical minocycline with priority review designation to obtain marketing approval from the NMPA. The indication of CU-10201 is for the treatment of non-nodular moderate to severe acne vulgaris in pediatric and adult patients aged nine and over.

– Minocycline is a tetracycline antibiotic used to treat a number of bacterial infections and acne vulgaris. The currently available minocycline products are mostly oral medications. Compared to other major anti-acne antibiotics and conventional oral drugs, topical minocycline foam has lower systemic drug exposure, fewer side effects, lower rate of drug resistance, and likely higher patient compliance.

– CU-10201 obtained marketing approval from the NMPA in November 2024. We are currently actively preparing for its commercialization activities in China.

– The marketing approval of CU-10201 was primarily based on the results of a Phase III pivotal clinical trial completed in China. The clinical trial demonstrated that CU-10201 has a significant efficacy and a favorable safety profile in the treatment of acne.

CU-10101 (topical novel small molecule agent)

– CU-10101 is a non-hormonal, small molecule drug for the treatment of mild to moderate atopic dermatitis. The non-hormonal properties of CU-10101 may reduce the side effects and restrictions associated with corticosteroids and its localized topical formulation allows the medication to reach the affected areas directly.

– The IND application of CU-10101 was approved by the CDE in May 2024, and we completed the first patient enrollment in Phase I clinical trial in China in September 2024.

Topical Anesthesia

CU-30101 (localized topical lidocaine and tetracaine cream)

– CU-30101 is a localized lidocaine and tetracaine compound topical anesthesia cream for topical anesthesia operations. The formulation of lidocaine and tetracaine combination in CU-30101 may produce rapid and long-lasting anesthetic effects due to its ingredients' unique pharmacokinetic properties.

– Lidocaine diffuses more rapidly, and more extensively than tetracaine, whereas tetracaine, a long-acting localized amino ester type anesthetic, is more lipophilic than lidocaine and can be concentrated in the topical stratum corneum. Systemic absorption of the anesthetic component ingredients is also limited from the topical cream formulation.

– The Phase III clinical trial of CU-30101 in China was completed in January 2024 and its drug marketing authorization application was accepted by the NMPA in July 2024.

– The drug marketing authorization application for CU-30101 was primarily based on the results of its Phase III pivotal clinical trial completed in China. The clinical trial showed that CU-30101 was as effective as its control and reference drug Pliaglis® lidocaine and tetracaine cream in analgesia and demonstrated an overall favorable safety profile.

Localized Adipose Accumulation Management

Core Product CU-20401 (recombinant mutant collagenase)

– CU-20401 is a recombinant mutant collagenase that targets localized adipose accumulation associated metabolic diseases. CU-20401 adopts an alternative mechanism of action where it acts as a collagenase to selectively act on the extracellular matrix attached to adipose tissue. After localized injection, CU-20401 degrades extracellular matrix collagen in the subcutaneous fat layer which leads to apoptosis of adipocytes, and is expected to effectively reduce localized adipose accumulation.

– CU-20401 is technologically modified with reduced rate to catalyze the collagen degradation with mild catalytic activity, thus reducing the adverse effects of wild-type collagenase, such as bruising and pain.

– In December 2024, we completed the Phase II clinical trial for submental adipose accumulation in China, and we expect to obtain its regulatory approval for commercialization in China in 2028. In the Phase II clinical trial, CU-20401 demonstrated significant and robust efficacy advantages with a favorable safety profile. In terms of efficacy, the treatment efficacy of different doses of CU-20401 was superior to that of the placebo group, with statistically significant differences in efficacy. During the follow-up period, as the follow-up time extended, the treatment efficacy of CU-20401 at different doses showed more significant improvement compared to baseline, and the treatment benefits were also greater than those of the placebo group. Preliminary observations from the clinical trial also indicated a dose-response trend. In terms of safety, the overall safety profile of CU-20401 was favorable, with no dosage-related differences in the incidence rate or severity level of adverse events observed.

Warning: There is no assurance that the core product and each of the pipeline products will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

Commercialization

We have adopted a well-tailored commercialization strategy to penetrate the broader dermatology treatment and care market in China. Our pivotal research results have been consecutively selected for the Annual Meeting of Chinese Society of Dermatology and the Annual Meeting of China Dermatologist Association & National Congress of Cosmetic Dermatology. This highlights our influence in the industry and advanced standing in the field of dermatology, which can attract more customers. Our Scientific Advisory Committee consists of top dermatologists from numerous third-class hospitals, which helps to build consumers' trust. To align with the product approval timeline, we have proactively established a dedicated marketing team with strong market insights and marketing capabilities, covering various provinces. This team is able to respond quickly to market changes and has successfully developed partnerships with hundreds of institutions and hundreds of hospitals across China. Online marketing has always been one of our strategic priorities. We continue to deliver excellent marketing output and extensive science education on various e-commerce platforms and social media platforms such as Tmall, JD, Bilibili, Douyin, Zhihu and Xiaohongshu, enabling precise conversion of potential customers. In addition, our customer service team provides customers with professional and suitable products to optimize customer experience, increase repurchase rate and strengthen brand stickiness.

With strong product capabilities, sales and operational strengths, the Company has continued to launch blockbuster products. In the sector of scalp diseases and care, we have established and refined our product portfolio, along with outstanding performances from individual products. In addition, CU-40102 (topical finasteride spray) obtained marketing approval from the NMPA in June 2025 and from the Hong Kong Department of Health in August 2025, respectively. It can reduce the systemic exposure of the drug compared with oral formulations. We believe that CU-40102, as a topical treatment, will be more acceptable to patients with androgenetic alopecia, offering a new alternative in their treatment options. In the sector of skin diseases and care, CU-10201 (topical 4% minocycline foam) obtained marketing approval from the NMPA in November 2024. Compared to other major anti-acne antibiotics and conventional oral drugs, topical minocycline foam has lower systemic drug exposure, fewer side effects, a lower rate of drug resistance, and likely higher patient compliance.

Our comprehensive commercialized product portfolio could address distinctive demands from a wide range of population groups as their needs evolve with disease progression or improvement to gain customer stickiness. From pre-sales product consultations, in-use guidance, to post-sales feedback, our customer service team provides professional guidance and emotional support tailored to customers' specific needs throughout the entire product usage cycle. This approach not only optimizes the customer experience but also further enhances product repurchase rate and brand recognition.

Manufacturing Facilities

Our commercial-scale GMP manufacturing facilities with three drug product production lines in Jiangsu Province have commenced operation in 2023. The three production lines cover topical cream, ointment, aerosol, and foam products. The flow and control of the entire manufacturing processes are designed to be compliant with the latest GMP requirements, ensuring that our production can meet the clinical and marketing approval requirements of various drug regulatory authorities (including the NMPA, FDA and European Medicines Agency). We believe the production capacity of such manufacturing facilities can support our clinical trials and near-term commercialization plans for our drug candidates.

In addition, Cutia Wuxi, a wholly-owned subsidiary of the Company, has obtained the "Drug Manufacturing Certificate (藥品生產許可證)" issued by the Jiangsu Medical Products Administration in April 2024, which is expected to play a long-term constructive role in production capacity expansion and market development of the Company, thus laying the foundation for subsequent commercialization of our product candidates.

KEY EVENTS AFTER THE REPORTING PERIOD

In August 2025, CU-40102 (topical finasteride spray) obtained marketing approval from the Hong Kong Department of Health, with an approved indication for the treatment of androgenetic alopecia. This is another significant milestone for CU-40102 following the marketing approval obtained from the NMPA. This approval will accelerate CU-40102's global expansion, broaden its market reach, and benefit more patients with androgenetic alopecia.

Save as disclosed above, there are no significant events affecting the Group occurred since the Reporting Period and up to the date of this announcement.

FUTURE DEVELOPMENT

We are dedicated to providing consumers and patients with safe and comprehensive dermatology treatment and care solutions. Looking forward to the second half of 2025, we will continue to strengthen the commercialization activities of CU-10201 (topical 4% minocycline foam) and CU-40102 (topical finasteride spray), enabling patients and consumers to access our products at the earliest possible. By leveraging our established online channels and pre-arranged offline channels, we aim to accelerate the rapid market expansion of our products, thereby significantly enhancing not only our brand recognition but also the competitiveness and influence of our products. CU-30101 (localized topical lidocaine and tetracaine cream) is anticipated to receive regulatory approval for commercialization in China and we are proactively coordinating market launch initiatives to ensure seamless connection to our existing sales platforms. We hope to deliver a comprehensive portfolio of products that addresses the changing and diverse therapeutic needs of patients and consumers by expanding our sales network more extensively.

Furthermore, CU-20401 (recombinant mutant collagenase) has demonstrated a favorable safety and efficacy profiles in its Phase II clinical trial conducted in China. Based on the positive outcomes of the Phase II clinical trial, the Group will further explore CU-20401's therapeutic advantages and expedite the progression to Phase III clinical trial. We will also fully leverage our R&D strengths to systematically promote the clinical progress of the remaining pipeline candidates.

We are optimistic on the market potential of the online and offline channels and will continue to adhere to our core marketing strategy of online and offline marketing while exploring online-to-offline marketing combination and leverage the synergistic advantages of multiple products to drive robust overall sales growth. We will also continue to strengthen our sales capabilities and actively develop online marketing campaigns on various e-commerce platforms and social media platforms to increase brand awareness. In addition, we will work closely with renowned physicians to conduct product demonstrations and trainings.

Leveraging on our CATAME® technology platform, our integrated commercialization model, in-depth industry experience and the determination of our team, we believe we can seize the opportunities arising from the rapid expansion of China's sales network, provide innovative solutions for patients and generate higher returns to our Shareholders.

FINANCIAL REVIEW

Revenue

Our revenue was substantially generated from the sale of our in-licensed and distributed scalp diseases and care products and certain skin care products ("**Routine Skin Care Products**"). Revenue of the Group decreased by 30.6% from approximately RMB95.6 million for the six months ended 30 June 2024 to approximately RMB66.3 million for the six months ended 30 June 2025, which was primarily due to the Group's prudent decision to terminate its agency cooperation with US skincare brand Phyto-C under the influence of macroeconomic policies and international environmental factors, while reallocating resources to commercialization preparations for newly approved products, including CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam). These products are projected to demonstrate greater market potential and higher return on investment ratios, with this adjustment expected to benefit the Group's medium-to-long term development.

Cost of Sales

Our cost of sales primarily consisted of purchase costs and logistics costs related to our scalp diseases and care products, and Routine Skin Care Products. For the six months ended 30 June 2025, we recorded cost of sales of approximately RMB34.2 million, representing a decrease of approximately 24.3% from approximately RMB45.2 million for the six months ended 30 June 2024. Such decrease was in line with the change of our revenue trend.

Gross Profit and Gross Profit Margin

Gross profit represents our revenue less our cost of sales. Gross profit margin represents our gross profit as a percentage of our revenue. Our gross profit amounted to approximately RMB32.1 million for the six months ended 30 June 2025, representing a decrease of 36.3% from approximately RMB50.3 million for the six months ended 30 June 2024. Our gross profit margin was 53% and 48% for the six months ended 30 June 2024 and the six months ended 30 June 2025, respectively, which fluctuated with the change in the product portfolio mix but remained stable overall.

Other Income and Gains

Our other income primarily consisted of interest income and government grants. The government grants mainly represent subsidies received from local government authorities for that relate to both expenses and assets. Our interest income comprises (i) bank interest income; (ii) deemed interest income from loans to employees and related parties; and (iii) imputed interest income on rental and other deposits. Other income of the Group decreased by 10.7% from approximately RMB11.9 million for the six months ended 30 June 2024 to approximately RMB10.6 million for the six months ended 30 June 2025, which was primarily due to the decrease in our bank interest income.

Our gains primarily consisted of our fair value gains on financial assets at fair value through profit or loss ("**FVTPL**"). Other gains decreased by 58.9% from approximately RMB11.8 million for the six months ended 30 June 2024 to approximately RMB4.9 million for the six months ended 30 June 2025, which was primarily due to a decrease in fair value gains on financial assets at FVTPL.

Selling and Distribution Expenses

Our selling and distribution expenses consisted of staff costs, share-based payments expenses, marketing expenses and others. Our selling and distribution expenses decreased by 11.4% from approximately RMB103.5 million for the six months ended 30 June 2024 to approximately RMB91.7 million for the six months ended 30 June 2025, which was primarily due to a decrease in the share-based payment expenses resulting from the vesting of a portion of share options and restricted share units under the Pre-IPO Equity Incentive Plan. Meanwhile, the Company is actively optimizing the return on investment ratios of several products and rationally investing in channel expansion and marketing preparations for products approaching commercialization (including CU-40102 and CU-10201, etc.).

Research and Development Costs

Our research and development costs consisted of staff costs, share-based payment expenses, acquisition/licensing-in expenses, third-party contracting costs, depreciation and amortization and others. For the six months ended 30 June 2025, we recorded research and development costs of approximately RMB78.9 million, representing a decrease of 20.3% as compared to approximately RMB99.0 million for the corresponding period of 2024, which was primarily due to (i) a decrease in the share-based payment expenses resulting from the vesting of a portion of share options and restricted share units under the Pre-IPO Equity Incentive Plan; and (ii) a decrease in acquisition/licensing-in expenses in line with the achievement of key milestones.

Set out below are the components of research and development costs for the periods indicated:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Staff costs	**25,181**	27,802
Share-based payment expenses	**6,489**	11,809
Acquisition/licensing-in expenses	**7,258**	24,385
Third-party contracting costs	**26,337**	18,972
Depreciation and amortization	**9,891**	11,487
Others	**3,724**	4,553
Total	**78,880**	99,008

Administrative Expenses

Our administrative expenses consisted of staff costs, share-based payment expenses, consulting fees, depreciation and amortization and others. Administrative expenses decreased by 5.0% from approximately RMB67.6 million for the six months ended 30 June 2024 to approximately RMB64.2 million for the six months ended 30 June 2025, which was primarily due to the decrease in the share-based payment expenses resulting from the vesting of a portion of share options and restricted share units under the Pre-IPO Equity Incentive Plan.

Set out below are the components of administrative expenses for the periods indicated:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Staff costs	**25,378**	23,752
Share-based payment expenses	**10,791**	21,111
Consulting fees	**8,290**	7,943
Depreciation and amortization	**11,114**	7,153
Others	**8,675**	7,641
Total	**64,248**	67,600

Impairment Losses on Financial Assets, net

Our impairment losses on financial assets, approximately RMB7.2 million for the six months ended 30 June 2025, were the impairment losses under the expected credit loss model, net of reversal, related to our trade receivables (for the six months ended 30 June 2024: nil).

Other Expenses

Our other expenses primarily consist of (i) write-down of inventories to net realisable value; (ii) net foreign exchange losses, primarily related to our bank balances and time deposits over three months denominated in the U.S. dollars; (iii) loss on disposal of items of property, plant and equipment; and (iv) loss on termination of a lease contract. Our other expenses was approximately RMB0.03 million and RMB40.0 million for the six months ended 30 June 2024 and the six months ended 30 June 2025, respectively, which was primarily due to the increase in write-down of inventories.

Finance Costs

Our finance costs mainly include interests on bank loans and lease liabilities. Finance costs increased by 2.1% from approximately RMB4.8 million for the six months ended 30 June 2024 to approximately RMB5.0 million for the six months ended 30 June 2025, which was primarily due to the increase in bank loans obtained to finance our daily operation.

Income Tax Expenses

Our income tax expense for the six months ended 30 June 2025 was nil (for the six months ended 30 June 2024: nil).

Loss for the Period

As a result of the foregoing, we recorded a loss of approximately RMB239.4 million for the six months ended 30 June 2025, representing an increase of approximately 19.1% from a loss of approximately RMB200.9 million for the six months ended 30 June 2024.

Non-IFRS Measure

To supplement our condensed consolidated financial statements which are presented in accordance with IFRS Accounting Standards, we also use adjusted net loss for the period, a non-IFRS measure to present our operating performance. Adjusted net loss for the period, as an additional financial measure, is not required by, or presented in accordance with IFRS Accounting Standards. We believe that such non-IFRS measure facilitates comparisons of our operating performance from period to period by eliminating impacts of non-cash or non-recurring items that our management considers to be not indicative of our operating performance and provides useful information to Shareholders and investors to evaluate our operating results in the same manner as our management does. However, our presentation of the adjusted net loss for the period may not be comparable to similarly titled measures presented by other companies. The use of such non-IFRS measure has limitations as an analytical tool, and Shareholders and investors should not consider it in isolation, or as substitute for analysis of, our results of operations or financial position as reported under IFRS Accounting Standards. We define adjusted net loss for the period as loss for the period adjusted by adding back share-based payment expenses.

The following table reconciles our non-IFRS adjusted net loss for the period with our loss for the periods indicated:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss for the period	**(239,387)**	(200,926)
Add:		
Share-based payment expenses	**21,124**	39,917
Non-IFRS adjusted net loss for the period	**(218,263)**	(161,009)
Proportion of non-IFRS adjusted net loss to revenue for the period *(Note)*	**(3.29)**	(1.68)

Note:

Share-based payment expenses relates to the share options and restricted share units granted by the Company under its equity incentive plans, which the management considers that to be a non-cash item.

Liquidity and Financial Resources

Our primary uses of cash were to fund (i) R&D activities of our product candidates; and (ii) our daily operation and commercial promotion activities. We financed our operations primarily through equity financing, bank borrowings and cash generated from sale of our products. We monitor and maintain a level of cash and cash equivalents deemed adequate to mitigate the effects of fluctuations in cash flows. Currently, we follow a set of funding and treasury policies to manage our capital resources and mitigate potential risks involved.

As of 30 June 2025, our total cash and cash equivalents amounted to approximately RMB208.8 million, representing a decrease of 45.9% as compared to approximately RMB385.7 million as of 31 December 2024, which was primarily due to expenditures on research and development, selling and distribution and other operating activities.

As of 30 June 2025, our time deposits over three months amounted to approximately RMB10.7 million, representing an increase of 1.5% as compared to approximately RMB10.5 million as of 31 December 2024, which was primarily due to the increase in accrued interest receivable.

As of 30 June 2025, our financial assets at FVTPL amounted to approximately RMB462.0 million, representing a decrease of 3.7% as compared to approximately RMB480.0 million as of 31 December 2024, which was primarily due to the withdrawal of the financial assets, partially offset by the fair value gains during the period.

As of 30 June 2025, our current assets amounted to approximately RMB822.5 million, including cash and cash equivalents of approximately RMB208.8 million. Our current liabilities amounted to approximately RMB260.0 million, including interest-bearing bank borrowings of approximately RMB196.3 million.

Details of the maturity profile of interest-bearing bank borrowings as of 30 June 2025 are set out in Note 11 to the financial statements.

Indebtedness

The following table sets forth the breakdown of our lease liabilities and interest-bearing bank borrowings as of the dates indicated:

	As of 30 June 2025	As of 31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Lease liabilities	**58,498**	57,636
Interest-bearing bank borrowings	**231,907**	263,303

Except as discussed above, we did not have any other material mortgages, charges, debentures, loan capital, debt securities, loans, bank overdrafts or other similar indebtedness, finance lease or hire purchase commitments, liabilities under acceptance (other than normal trade bills), acceptance credits, which are either guaranteed, unguaranteed, secured or unsecured, or guarantees or other contingent liabilities as of 30 June 2025.

Gearing Ratio

As of 30 June 2025, our gearing ratio was 32.2%, as compared with 30.0% as of 31 December 2024. The gearing ratio was fluctuating but remains stable overall. Gearing ratio is calculated by dividing total liabilities by total assets and multiplying the product by 100%.

Significant Investments, Material Acquisitions and Disposal

On 13 June and 16 June 2023, the Company had subscribed for the wealth management products in the aggregate amount of US$63,840,000 offered by different funds. Each of the wealth management products is characterized by its nature of principal-and-return-guaranteed, and the Subscriptions were funded by the Group's surplus cash reserves for treasury management purpose in order to maximize its return on the surplus capital. For further details, please refer to the announcement of the Company dated 28 August 2023.

The following are the details of the performance of the wealth management products held by the Group with size relative to the total assets of the Group above or equal 5% as of 30 June 2025:

Relevant fund	Subscription date	Principal amount of subscription *(USD'000)*	Realised gain during the Reporting Period *(USD'000)*	Unrealised gain during the Reporting Period *(USD'000)*	Fair value as at 30 June 2025 *(USD'000)*	Size relative to the total assets of the Group as of 30 June 2025 *(%)*
Alpha Generation	13 June 2023	14,200	–	211	15,066	10
Innovation Prosperity	13 June 2023	14,200	–	211	15,066	10
Oriental Kylin	13 June 2023	14,200	–	211	15,066	10
Summit View	16 June 2023	14,400	–	214	15,268	10

The Company did not receive any dividend from the above funds during the six months ended 30 June 2025.

Save as disclosed above, we did not hold any significant investments as defined under the Listing Rules, and we did not have any material acquisitions or disposals of subsidiaries, associates and joint ventures for six months ended 30 June 2025.

Capital Commitments

As of 30 June 2025, we had capital commitment of approximately RMB4.8 million for the contracts in relation to acquisition of property, plant and equipment and other intangible assets (as of 31 December 2024: RMB5.0 million).

Contingent Liabilities

As of 30 June 2025, we did not have any material contingent liabilities, guarantees or any litigation against us (as of 31 December 2024: nil).

Pledge of Assets

As of 30 June 2025, we did not pledged or charged any assets (as of 31 December 2024: nil).

Foreign Exchange Exposure

Foreign currency risk refers to the risk of loss resulting from changes in foreign currency exchange rates. Fluctuations in exchange rates between RMB and other currencies in which the Group conducts business may affect our financial condition and results of operation. The Group mainly operates in the PRC and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to Hong Kong dollars and the U.S. dollars. The conversion of foreign currencies into RMB, including Hong Kong dollars and the U.S. dollars, has been based on rates set by the People's Bank of China. The Group primarily limits our exposure to foreign currency risk by closely monitoring the foreign exchange market. For the six months ended 30 June 2025, the Group did not enter into any currency hedging transactions.

Employees and Remuneration

As of 30 June 2025, the Group had a total of 298 employees. The total remuneration cost of the Group for the six months ended 30 June 2025 was approximately RMB90.6 million, as compared to approximately RMB113.7 million for the six months ended 30 June 2024, which was primarily due to the decrease in share-based payment expenses. The following table sets forth the total number of employees by function as of 30 June 2025:

Function	Number	Percentage of total
R&D	38	12.7%
Manufacturing and Quality Control	56	18.8%
Medical and Regulatory Affairs	44	14.8%
Sales, Marketing and Administration	160	53.7%
Total	298	100.0%

The remuneration of the employees of the Group comprises salaries, bonuses, employees' provident fund, share-based payment, social security contributions and other welfare payments. In accordance with applicable laws and regulations, we made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for the Group's employees. Two equity incentive plans, namely Pre-IPO Equity Incentive Plan and Post-IPO Equity Incentive Plan were adopted by the Company to incentivize and reward our employees and to align their interests with that of the Company.

Use of Proceeds

The Group received net proceeds (after deduction of underwriting commissions and related costs and expenses) from the global offering of approximately HK$392.7 million (equivalent to approximately RMB356.8 million). Such net proceeds were used, and are proposed to be used accordingly to the intentions previously disclosed in the section headed "Future Plans and Use of Proceeds" in the Prospectus of the Company. As of 30 June 2025, such net proceeds were utilized as follows:

Use of proceeds from the listing	Amount of net proceeds for planned applications *(HK$ million)*	Percentage of total net proceed *(%)*	Unutilized net proceeds as of 1 January 2025 *(HK$ million)*	Utilized net proceeds during the Reporting Period *(HK$ million)*	Utilized net proceeds as of 30 June 2025 *(HK$ million)*	Unutilized net proceeds as of 30 June 2025 *(HK$ million)*	Expected time frame for unutilized amount
For the Core Product							
1. For funding the costs and expenses in connection with R&D personnel as well as continuing R&D activities of CU-20401	164.9	42.0	104.1	15.1	75.9	89.0	by the end of 2029
2. For the local production of CU-20401 in Mainland China	11.8	3.0	11.8	–	–	11.8	by the end of 2029
For the Key Products							
1. For funding the costs and expenses in connection with R&D personnel as well as continuing R&D activities of CU-40102 and CU-10201	43.2	11.0	10.8	10.8	43.2	–	by the end of 2026
2. For milestone payments of CU-10201	43.2	11.0	35.2	8.0	16.0	27.2	by the end of 2026
For the other candidates in the pipeline							
1. For the continuing R&D activities of CU-40101, CU-40103, CU – 40104 and other potential scalp diseases and care products	28.3	7.2	7.3	5.3	26.3	2.0	by the end of 2028
2. For the continuing R&D activities of CU-10101, CU-10401 and other potential skin diseases and care products	28.3	7.2	16.3	3.3	15.3	13.0	by the end of 2028
3. For the continuing R&D activities of CU-30101	14.1	3.6	–	–	14.1	–	
For technology development and business development for pipeline expansion	**39.3**	**10.0**	**10.1**	**10.1**	**39.3**	**–**	
For our working capital and other general corporate purposes	**19.6**	**5.0**	**–**	**–**	**19.6**	**–**	
Total	**392.7**	**100.0**	**195.6**	**52.6**	**249.7**	**143.0**	

OTHER INFORMATION

Compliance with the Corporate Governance Code

The Company has adopted the principles and code provisions in the Corporate Governance Code and has complied with all applicable code provisions for the six months ended 30 June 2025.

Model Code for Securities Transactions

The Company has adopted the Model Code as its own code of conduct regarding securities transactions by the Directors. Having made specific enquiries with all Directors, each of them has confirmed that he/she has complied with the Model Code during the six months ended 30 June 2025. No incident of non-compliance of the Model Code by the employees who are likely to be in possession of inside information was noted by the Company.

Purchase, Sale or Redemption of Listed Securities

In 2024, the Company has repurchased a total of 1,362,600 Shares (the "**Repurchased Shares**") on the Stock Exchange (the "**Share Repurchase**"). The aggregate purchase price paid for the Repurchased Shares was approximately HK$15.1 million. The Repurchased Shares represented approximately 0.44714% of the issued Shares (excluding treasury Shares) as at the date of the resolution granting the repurchase mandate. As of 30 June 2025, the 1,362,600 Repurchased Shares were accounted for as treasury shares of being used for incentives for eligible participants, sale or transfer to obtain liquidity and other purposes.

Save as disclosed above, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including sale of treasury Shares) for the six months ended 30 June 2025.

REVIEW OF FINANCIAL INFORMATION

Audit Committee

The Board has established the Audit Committee which comprises Mr. Chung Ming Kit (chairman), Mr. Zhang Zhisong (appointed on 28 August 2025) and Mr. Ye Xiaoxiang, who are all our independent non-executive Directors. Mr. Tao Tak Yan Dennis, a former member of the Audit Committee, has resigned with effect from 28 August 2025. The primary duties of the Audit Committee are to review and supervise the Company's financial reporting process, risk management and internal controls.

The Audit Committee, together with the management of the Company, has reviewed the accounting principles and practices adopted by the Group and discussed risk management, internal control and financial reporting matters with management including a review of the unaudited interim condensed consolidated financial information of the Group for the six months ended 30 June 2025.

Scope of Work of Ernst & Young

The Company's external auditor, Ernst & Young, has performed an independent review of the Group's interim financial information for the Reporting Period in accordance with Hong Kong Standard on Review Engagement 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants.

Interim Dividend

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2025 (30 June 2024: nil).

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.cutiatx.com).

The interim report of the Company for the six months ended 30 June 2025 containing all the information required by the Listing Rules will be made available to the Shareholders through e-mail or express delivery and will be published on the respective websites of the Stock Exchange and the Company in due course.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2025

	Notes	**2025**	2024
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
Revenue	*4*	**66,290**	95,575
Cost of sales		**(34,225)**	(45,240)
Gross profit		**32,065**	50,335
Other income and gains	*4*	**15,484**	23,707
Selling and distribution expenses		**(91,659)**	(103,486)
Research and development costs		**(78,880)**	(99,008)
Administrative expenses		**(64,248)**	(67,600)
Impairment losses on financial assets, net		**(7,180)**	–
Other expenses		**(40,019)**	(28)
Finance costs		**(4,950)**	(4,846)
LOSS BEFORE TAX		**(239,387)**	(200,926)
Income tax expense	*5*	**–**	–
LOSS AND TOTAL COMPREHENSIVE LOSS FOR THE PERIOD		**(239,387)**	(200,926)
Attributable to:			
Owners of the parent		**(239,387)**	(200,926)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT			
Basic and diluted (RMB)	*7*	**(0.75)**	(0.66)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2025

	Notes	**30 June 2025** ***RMB'000*** **(Unaudited)**	31 December 2024 *RMB'000* (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment		**161,810**	173,267
Right-of-use assets		**46,209**	47,662
Other intangible assets		**8,410**	8,895
Amounts due from related parties		**36,397**	36,431
Prepayments, other receivables and other assets		**40,888**	39,865
Total non-current assets		**293,714**	306,120
CURRENT ASSETS			
Inventories		**63,236**	74,692
Trade receivables	*8*	**36,632**	99,164
Prepayments, other receivables and other assets		**39,746**	35,747
Amounts due from related parties		**1,397**	1,363
Financial assets at FVTPL	*9*	**461,994**	479,955
Time deposits over three months		**10,684**	10,530
Cash and cash equivalents		**208,837**	385,670
Total current assets		**822,526**	1,087,121

	Notes	**30 June 2025** ***RMB'000*** **(Unaudited)**	31 December 2024 *RMB'000* (Audited)
CURRENT LIABILITIES			
Trade and other payables	*10*	**51,175**	97,572
Lease liabilities		**12,564**	12,376
Interest-bearing bank borrowings	*11*	**196,267**	213,303
Total current liabilities		**260,006**	323,251
NET CURRENT ASSETS		**562,520**	763,870
TOTAL ASSETS LESS CURRENT LIABILITIES		**856,234**	1,069,990
NON-CURRENT LIABILITIES			
Lease liabilities		**45,934**	45,260
Deferred income		**18,040**	–
Interest-bearing bank borrowings	*11*	**35,640**	50,000
Total non-current liabilities		**99,614**	95,260
Net assets		**756,620**	974,730
EQUITY			
Equity attributable to owners of the parent			
Share capital		**45**	45
Treasury shares		**(13,857)**	(13,857)
Reserves		**770,432**	988,542
Total equity		**756,620**	974,730

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

1. CORPORATE INFORMATION AND BASIS OF PREPARATION

1.1 Corporate information

Cutia Therapeutics (the "**Company**") was incorporated in the Cayman Islands as an exempted company with limited liability on 15 May 2019, and its shares are listed on The Stock Exchange of Hong Kong Limited on 12 June 2023. The registered office address of the Company is 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands. The Company is an investment holding company.

The Company and its subsidiaries (the "**Group**") are principally engaged in developing innovative and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market.

1.2 Basis of preparation

The interim condensed consolidated financial information for the six months ended 30 June 2025 has been prepared in accordance with International Accounting Standard 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2024.

This interim condensed consolidated financial information is presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand except when otherwise indicated.

2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group' annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of the following amended IFRS Accounting Standard for the first time for the current period's financial information.

Amendments to IAS 21	*Lack of Exchangeability*

The nature and impact of the amended IFRS Accounting Standard are described below:

Amendments to IAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted with and the functional currencies of group entities for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the interim condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

Operating segment information

For management purposes, the Group has only one reportable operating segment, which is developing innovative and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. Since this is the only reportable operating segment of the Group, no further operating segment analysis thereof is presented.

Geographical information

During the Reporting Period, all of the Group's revenue was derived from customers located in the People's Republic of China ("**PRC**") and nearly all of the Group's non-current assets were located in the PRC, and therefore no geographical segment information is presented in accordance with IFRS 8 *Operation Segments*.

Information about major customers

Revenue derived from sales to customers, which amounted to more than 10% of the Group's revenue during the six months ended 30 June 2025 and 2024, is as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Customer A	**N/A***	21,307
Customer B	**N/A***	12,711

* The corresponding revenue did not amount to more than 10% of the total revenue of the Group for the six months ended 30 June 2025.

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue from contracts with customers		
Sale of products – at a point in time	**66,290**	95,575

An analysis of other income and gains is as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Other income		
Government grants	**7,173**	3,739
Bank interest income	**2,292**	6,326
Imputed interest income on rental and other deposits	**79**	247
Deemed interest income from loans to employees	**134**	128
Deemed interest income from the loans to related parties	**681**	650
Others	**275**	819
Total other income	**10,634**	11,909
Gains		
Foreign exchange gains, net	**–**	1,234
Fair value gains on financial assets at FVTPL	**4,850**	10,564
Total gains	**4,850**	11,798
Total other income and gains	**15,484**	23,707

5. INCOME TAX

The Company was incorporated in the Cayman Islands and is exempted from income tax.

No Hong Kong profits tax was provided for as there was no estimated assessable profit of the Group's Hong Kong subsidiary that was subject to Hong Kong profits tax during the periods presented in the interim condensed consolidated financial information.

No PRC Enterprise Income tax was provided for as there was no estimated assessable profit of the Group's PRC subsidiaries during the periods presented in the interim condensed consolidated financial information.

Deferred taxation had not been fully recognised on the unused tax losses and deductible temporary differences since it is not probable that the taxable profits will be available against which the tax losses and deductible temporary differences can be utilised in the foreseeable future.

6. DIVIDENDS

No dividend was paid or proposed for ordinary shareholders of the Company during the six months ended 30 June 2025, nor has any dividend been proposed since the end of the Reporting Period (during the six months ended 30 June 2024: nil).

7. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amounts for the six months ended 30 June 2025 and 2024 is based on the loss for the period attributable to ordinary equity holders of the parent and the weighted average numbers of ordinary shares outstanding.

No adjustment has been made to the basic loss per share amounts presented for the six months ended 30 June 2025 and 2024 in respect of a dilution as the impact of share options and restricted share units had an anti-dilutive effect on the basic loss per share amounts presented.

The calculations of basic and diluted loss per share are based on:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss		
Loss attributable to ordinary equity holders of the parent for the purpose of calculating basic and diluted loss per share (RMB'000)	**(239,387)**	(200,926)
Shares		
Weighted average number of ordinary shares outstanding during the period used in the basic and diluted loss per share calculation	**318,779,613**	304,730,777
Loss per share (basic and diluted) (RMB per share)	**(0.75)**	(0.66)

8. TRADE RECEIVABLES

An ageing analysis of the trade receivables as at the end of the Reporting Period, based on the invoice date and net of loss allowance, is as follows:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 1 month	**8,709**	54,610
1 month to 6 months	**10,627**	43,971
6 months to 12 months	**17,225**	500
Over 12 months	**71**	83
Total	**36,632**	99,164

9. FINANCIAL ASSETS AT FVTPL

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Financial products	**461,994**	479,955

The financial assets measured at FVTPL represented financial products with no predetermined return which are principal protected investments. The financial products are with expected yield rates, depending on the market prices of underlying financial instruments, including bonds, debentures and other financial assets. Hence their contractual cash flows do not qualify for solely payments of principal and interest. The expected yield rates ranged from 1.5% to 4.5% per annum as at 30 June 2025 (31 December 2024: 1.5% to 4.5% per annum).

10. TRADE AND OTHER PAYABLES

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade payables	**1,184**	12,821
Accrued expenses for research and development services	**17,504**	20,849
Payables for purchase of items of property, plant and equipment	**2,205**	7,175
Other payables	**16,299**	31,503
Salary and bonus payables	**5,242**	12,107
Other taxes payable	**2,191**	6,567
Accrued listing expenses	**6,550**	6,550
Total	**51,175**	97,572

An ageing analysis of the trade payables as at the end of each of the reporting periods, based on the invoice date, is as follows:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 3 months	**1,184**	12,821

11. INTEREST-BEARING BANK BORROWINGS

	30 June 2025			31 December 2024		
	Effective interest rate (%)	**Maturity**	**Amount *RMB'000* (Unaudited)**	Effective interest rate (%)	Maturity	Amount *RMB'000* (Audited)
Current						
Bank loans – unsecured	**1.80-2.90**	**2025-2026**	**122,383**	1.80-3.21	2025	167,603
Bank loans – unsecured	**–**	**–**	**–**	One-year LPR -105 bps	2025	5,700
Current portion of long term bank loans – secured (note)	**3.45**	**2026**	**40,000**	3.45	2025	40,000
Current portion of long term bank loans – unsecured	**One-year Loan prime rate ("LPR")-35 Basepoints ("bps")**	**2025-2026**	**1,004**	–	–	–
Current portion of long term bank loans – unsecured	**One-year LPR-30 bps**	**2025-2026**	**2,980**	–	–	–
Current portion of long term bank loans – unsecured	**One-year LPR-20 bps**	**2025-2026**	**29,900**	–	–	–
Total – current			**196,267**			213,303
Non-current						
Other secured bank loans (note)	**–**	**–**	**–**	3.45	2026	20,000
Bank loans – unsecured	**One-year LPR-35 bps**	**2027**	**8,910**	One-year LPR-20 bps	2026	30,000
Bank loans – unsecured	**One-year LPR-30 bps**	**2027**	**26,730**	–	–	–
Total – non-current			**35,640**			50,000
Total			**231,907**			263,303

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Analysed into:		
Bank loans repayable:		
Within one year or on demand	**196,267**	213,303
In the second year	**35,640**	50,000
Total	**231,907**	263,303

The carrying amounts of borrowings are denominated in the following currency:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
RMB	**231,907**	263,303

An analysis of the carrying amounts of borrowings by type of interest rate is as follows:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Fixed interest rate	**162,383**	227,603
Variable interest rate	**69,524**	35,700
Total	**231,907**	263,303

Note: The Company has guaranteed certain of the Group's bank loans up to RMB120,000,000 as at the end of the Reporting Period.

"Alpha Generation"	Alpha Generation Fund SPC (on behalf of Alpha Plus Fund SP); Alpha Generation Fund SPC is an exempted company with limited liability registered as a segregated portfolio company under the laws of the Cayman Islands on 25 April 2022
"androgenetic alopecia"	a common form of hair loss in both men and women
"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors of our Company
"CDE"	Center for Drug Evaluation of the NMPA (中國國家藥品監督管理局藥品審評中心), a division of the NMPA to review applications for clinical trials and drug marketing authorization
"China", "Chinese Mainland", or "PRC"	the People's Republic of China, but for the purpose of this announcement and for geographical reference only and except where the context requires, excluding Taiwan, the Macao Special Administrative Region and Hong Kong
"clinical trial(s)"	a research study for validating or finding the therapeutic effects and side effects of test drugs in order to determine the therapeutic value and safety of such drugs
"Company"	Cutia Therapeutics (科笛集團), an exempted company with limited liability incorporated under the laws of the Cayman Islands on 15 May 2019, the Shares of which are listed on the Main Board of the Stock Exchange (stock code: 2487)
"Core Product"	has the meaning ascribed to it under Chapter 18A of the Listing Rules; for the purpose of this announcement, our Core Product refers to CU-20401
"Corporate Governance Code"	the Corporate Governance Code contained in Appendix C1 to the Listing Rules, as amended, supplemented or otherwise modified from time to time
"Cutia Wuxi"	Cutia Therapeutics (Wuxi) Co., Ltd. (科笛生物醫藥(無錫)有限公司), a limited liability company established in the PRC on 4 December 2020 and a wholly-owned subsidiary of the Company
"dermatology"	the branch of medicine that deals with the diagnosis and treatment of skin related disorders
"DHT"	dihydrotestosterone, a male sex hormone which is the active form of testosterone, formed from testosterone in bodily tissue

"Director(s)"	the director(s) of the Company
"FDA"	Food and Drug Administration of the United States
"GMP"	good manufacturing practice, the practices required in order to conform to the guidelines recommended by agencies that control the authorization and licensing of the manufacture and sale of products
"Group", "our Group", "our", "we", or "us"	our Company and our subsidiaries
"HK$" or "Hong Kong Dollars"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong" or "HK"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong Department of Health"	the Department of Health of the Government of Hong Kong
"IFRS"	International Financial Reporting Standards
"IND"	investigational new drug, an application in the drug review process required by an regulatory authority to decide whether a new drug is permitted to initiate clinical trials; also known as clinical trial application, or CTA, in China
"indication"	a valid reason to use a specific test, drug, device, procedure or surgery
"Innovation Prosperity"	Innovation Prosperity Fund SPC (on behalf of Novelty Inspiration Fund SP); Innovation Prosperity Fund SPC is an exempted company with limited liability registered as a segregated portfolio company under the laws of the Cayman Islands on 13 May 2022
"Key Product(s)"	for the purpose of this announcement, our Key Products refer to CU-40102 and CU-10201
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
"mechanism of action"	the specific biochemical interaction through which a drug substance produces its pharmacological effect
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules, as amended, supplemented or otherwise modified from time to time

"NMPA"	the National Medical Products Administration of China (中國國家藥品監督管理局)
"Oriental Kylin"	Oriental Kylin Fund SPC (on behalf of Phoenix Fund SP); Oriental Kylin Fund SPC is an exempted company with limited liability registered as a segregated portfolio company under the laws of the Cayman Islands on 17 May 2022
"Phase I clinical trial"	a study in which a drug is introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and if possible, to gain an early indication of its efficacy
"Phase II clinical trial"	a study in which a drug is administered to a limited patient population to preliminarily evaluate the efficacy of the product for specific targeted diseases, to identify possible adverse effects and safety risks, and to determine optimal dosage
"Phase III clinical trial"	a study in which a drug is administered to an expanded patient population generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to provide adequate information for the labeling of the product
"Post-IPO Equity Incentive Plan"	the equity incentive plan adopted by the Company on 30 May 2023
"Pre-IPO Equity Incentive Plan"	the equity incentive plan adopted by the Company that took effect on 23 August 2019
"Prospectus"	the prospectus issued by the Company dated 31 May 2023
"R&D"	research and development
"Reporting Period"	the six months ended 30 June 2025
"RMB"	the lawful currency of the PRC
"Shares"	ordinary share(s) with nominal value of US$0.00002 each in the share capital of the Company
"Shareholders"	holder(s) of the Shares
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Subscription(s)"	Subscription(s) of the wealth management product(s) by the Company

"subsidiary(ies)"	has the meaning ascribed to it in section 15 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Summit View"	Summit View Fund SPC (on behalf of Distant View Fund SP); Summit View Fund SPC is an exempted company with limited liability registered as a segregated portfolio company under the laws of the Cayman Islands on 18 May 2023
"US" or "United States" or "the U.S."	the United States of America, its territories and possessions, any State of the United States, and the District of Columbia
"US$" or "U.S. dollars" or "USD"	the lawful currency of the U.S.

By order of the Board
Cutia Therapeutics
Zhang Lele
Chief Executive Officer and Executive Director

Hong Kong, 28 August 2025

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive Directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao and Ms. Yang Yunxia as non-executive Directors; and (iii) Mr. Chung Ming Kit, Mr. Zhang Zhisong and Mr. Ye Xiaoxiang as independent non-executive Directors.